arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


CURRENT CONCEPTS IN THE MANAGEMENT OF RETINAL VEIN OCCLUSION

  Presented by the Johns Hopkins University School of Medicine

Baruch D. Kuppermann, MD, PhD

Peter A. Campochiaro, MD

OVERVIEW

The retina specialty is morphing at extraordinary rates and is mainly being driven by the large-scale research efforts leading to new therapeutic strategies and several candidates in the clinical development pipeline. Results from 5 phase III studies on retinal vein occlusion (RVO) were recently announced. Namely, the National Institutes of Health’s SCORE (Standard Care vs Corticosteroid for RVO) study, 2 studies using dexamethazone intravitreal implant, the BRAVO (Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Branch RVO) trial, and the CRUISE (Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Central RVO) trial. Retina specialists treating patients with RVO have more therapeutic options, but are faced with a new dilemma: What treatment should I use? Lacking comparative, head-to-head data, the influx of information from clinical trials can be misleading. In order for clinicians to effectively treat patients with RVO, the educational gap between the most recent clinical research and results and then comparing and disseminating those results to clinicians must be filled. This CME activity is designed to help retina specialists aggregate, interpret, and apply the new data to their clinical practice.

GOAL

To provide retina specialists with up-to-date information on the management of RVO.

TARGET AUDIENCE

This activity is designed for retina specialists. No prerequisites required.

LEARNING OBJECTIVES

After completing this activity, the participant will demonstrate the ability to:

  • Discuss the results of the latest clinical trials for the management of RVOs.
  • Assess the safety and efficacy of ophthalmic steroid preparations.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

ACCREDITATION STATEMENT

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS

The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
After reviewing this online activity, participants may receive credit by completing the CME test, evaluation, and responding to the post-test questions correctly.

The estimated time to complete this activity: 30 minutes.

Release date: October 31, 2010. Expiration date: October 31, 2012.

FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Chairperson, Planners, and Participating Faculty reported the following:

Quan Dong Nguyen, MD, MSc (Chair)
Associate Professor of Ophthalmology
Diseases of the Retina and Vitreous, and Uveitis
Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, Maryland

Peter A. Campochiaro, MD
Professor, Department of Ophthalmology
Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, Maryland

Baruch D. Kuppermann, MD, PhD
Professor of Ophthalmology and Biomedical Engineering
Gavin Herbert Eye Institute
University of California, Irvine
Irvine, California

Participating Faculty Disclosures
Dr Campochiaro reports having individual consulting agreements with Amira Pharmaceuticals, Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc (DSMC – View 1); having institutional consulting agreements with Genentech, Inc and GlaxoSmithKline; and receiving research support from Alcon Laboratories, Inc, Alimera Sciences, Genentech, Inc, Genzyme Corporation, GlaxoSmithKline, Lpath, Inc, and Molecular Partners.

Dr Kuppermann reports receiving grants/research support from Alcon Laboratories, Inc, Alimera Sciences, Allergan, Inc, Genentech, Inc, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc, and Thrombogenics; and serving as a consultant for Allergan, Inc, Fovea Pharmaceuticals, Genentech, Inc, GlaxoSmithKline, Glaukos, NeoVista, Inc, Neurotech, Novartis Pharmaceuticals Corporation, Novagali Pharma, and Ophthotech Corporation.

Planner Disclosures
Dr Nguyen reports serving as a principal investigator on grants from Genentech, Inc, Heidelberg, Lux Biosciences, Inc, MacuSight, Inc, Novartis, and Regeneron, Inc; and serving as a consultant for Bausch & Lomb Incorporated and Santen Pharmaceutical Co, Ltd.

Dr Do reports serving as a principal investigator for grants/research support for Genentech Inc, Heidelberg, and Regeneron Pharmaceuticals, Inc; and serving as a consultant for Bausch & Lomb Incorporated.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION

The following faculty members have disclosed that their presentation will reference unlabeled/unapproved use of drugs or products:

Dr Campochiaro—ranibizumab and triamcinolone acetonide injectable suspension.
Dr Kuppermann—dexamethasone intravitreal implant, fluocinolone acetonide intravitreal implant, sustained-release fluocinolone acetonide, triamcinolone acetonide injectable suspension.

DISCLAIMER

The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

INTERNET CME POLICY

The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based activity. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.

INSTRUCTIONS

The following activity consists of 3 sections: a pre-test, 2 web-based presentations, and a CME post-test with an evaluation. All 3 sections must be completed to receive CME credit. A certificate of participation will be available online immediately following successful completion of the module.

Pre-Test

Emerging Clinical Trial Evidence for the Use of Corticosteroids for the Treatment of Macular Edema Related to Retinal Vein Occlusions
Baruch D. Kuppermann, MD, PhD

Management of Retinal Vein Occlusions
Peter A. Campochiaro, MD

Post-Test

Supported by an educational grant from Allergan, Inc.

procced to pretest
footer